Stereotaxis shares surge following trial completion

Stereotaxis (STXS) shares storm 37% higher after the company says that it's completed a 120-patient FDA trial for one of its cardiology navigation products - the Vdrive Robotic Navigation System with V-Loop Circular Catheter Manipulator.

The Vdrive with V-Loop system is designed for "remotely controlling the advancement, retraction, rotation, tip deflection, and loop size of a compatible catheter," Stereotaxis says. (PR)

Comments (1)
  • Envoy Global Research
    , contributor
    Comments (562) | Send Message
    The company completed a trial and is submitting this to the FDA for approval. Nothing really extraordinary. The stock reacts as if the product actually got approval, though I'm certain the company is hoping enough investors mistake a trial completion for FDA approval, as STXS is looking to sell more equity as per recent filings.
    7 Jan 2014, 09:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs